Skip to main content
. 2017 Aug 3;2(15):e94821. doi: 10.1172/jci.insight.94821

Figure 5. Anti-hCCR6 mAb prevents and inhibits imiquimod-induced psoriasis in hCCR6-Tg/mCCR6–/–mice.

Figure 5

(A) Representative images and H&E staining of back skin from hCCR6-Tg/mCCR6–/– mice treated with Vaseline (negative control, first column); imiquimod (IMQ) + isotype control mAb (second column); IMQ + anti–mIL-17 mAb (third column); or IMQ + h6H12 Fc-KO (fourth column) (5 mg/kg every 2 days). (B) Dorsal skin thickness was measured daily for 7 consecutive days. Data are representative of 3 independent experiments with 6 animals per group. (C) Therapeutic study of h6H12 Fc-KO and anti–mIL-17 mAbs (n = 10 per group) for the treatment of IMQ-induced psoriasis. Treatment (black arrows) was started 3 days after IMQ application (20% average change in skin thickness) and animals were monitored daily for skin thickness until day 8. Dorsal skin thicknesses were analyzed with the nonparametric Kruskal-Wallis ANOVA with the Dunn’s post-hoc test. **P < 0.01, ***P < 0.001.